ReviewNeurotrauma reports
Photobiomodulation Therapy for Traumatic Spinal Cord Injury: Current Evidence and Future Directions.
Review in Neurotrauma reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Photobiomodulation (PBM) therapy (PBMT) to treat traumatic spinal cord (SC) injury (tSCI) is a growing area of research that could present a highly effective therapy for restoring function after tSCI. SC injuries (SCIs) are severe injuries that typically result in the loss of motor, sensory, and autonomic function, dramatically affecting the lives of patients and their families. SCI has two primary parts: the primary injury, which occurs immediately at the time of injury and is a result of mechanical forces on the SC, and the secondary injury, which occurs over the months following the initial incident and is primarily the result of biochemical damage. PBM is the process through which nonionizing light is absorbed by naturally occurring chromophores in the body and causes beneficial physiological changes without causing thermal damage. In the case of tSCI, PBMT seems to work through increasing energy availability enabling normalized cellular function after tSCI reducing the functional loss from the secondary injury. When applied to tSCI, PBMT has been shown to improve the functional recovery after a tSCI. These beneficial effects have been shown extensively in rodent models across multiple studies using a variety of parameters. In order to translate this promising therapy to the clinical setting, multiple steps need to be taken including understanding dosing, establishing efficacy and safety in large animal models and humans, and the development of a clinical-grade PBMT application system. This review seeks to provide a comprehensive overview of the progress that has been made in the field of PBMT for tSCI and the steps needed to translate this promising therapy to the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.